Bookbuilding IPO | ₹214 Cr | Listed at NSE SME | Thu, May 21, 2026 - Mon, May 25, 2026
Q-Line Biotec IPO is a book build issue of ₹214.48 crores. The issue is entirely a fresh issue of 0.63 crore shares of ₹214.48 crore.
Q-Line Biotec IPO bidding started from May 21, 2026 and ended on May 25, 2026. The allotment for Q-Line Biotec IPO was finalized on May 26, 2026. The shares got listed on the NSE SME on May 29, 2026.
Q-Line Biotec IPO is set final issue price at ₹343 per share. The lot size for an application is 400 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,74,400 (800 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (1,200 shares), amounting to ₹4,11,600.
Hem Securities Ltd. is the book running lead manager and Purva Sharegistry (India) Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Hem Finlease Pvt.Ltd.
Refer to Q-Line Biotec IPO RHP for detailed Information.
IPO Open
Thu, May 21, 2026
IPO Close
Mon, May 25, 2026
Issue Price
₹343 per share
Market Cap (Pre-IPO)
₹800.16 Cr
| IPO Date | 21 to 25 May, 2026 |
| Listed on | Fri, May 29, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹326 to ₹343 |
| Issue Price | ₹343 per share |
| Lot Size | 400 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 62,53,200 shares (agg. up to ₹214 Cr) |
| Reserved for Market Maker | 3,13,200 shares Hem Finlease Pvt.Ltd. (agg. up to ₹11 Cr) |
| Fresh Issue (Ex Market Maker) | 59,40,000 shares (agg. up to ₹204 Cr) |
| Net Offered to Public | 59,40,000 shares (agg. up to ₹204 Cr) |
| Share Holding Pre Issue | 1,70,74,999 shares |
| Share Holding Post Issue | 2,33,28,199 shares |
| NSE Symbol | QLINE |
| ISIN | INE1G2W01011 |
Q-Line Biotec IPO comprises a total issue size of 62,53,200 shares. The net offer to the public is 59,40,000 shares, after excluding 3,13,200 shares allotted on a firm basis. Of the Net offer 29,69,200 (49.99%) are allocated to QIB, 8,91,600 (15.01%) allocated to NII 20,79,200 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 29,69,200 | 49.99% | 47.48% |
| − Anchor Investor Shares Offered | 17,81,200 | 28.48% | |
| − QIB (Ex. Anchor) Shares Offered | 11,88,000 | 19.00% | |
| NII (HNI) Shares Offered | 8,91,600 | 15.01% | 14.26% |
| − bNII > ₹10L | 5,94,400 | 9.51% | |
| − sNII < ₹10L | 2,97,200 | 4.75% | |
| Retail Shares Offered | 20,79,200 | 35.00% | 33.25% |
| Firm Reservations | |||
| Market Maker Shares Offered | 3,13,200 | 5.01% | |
| Total Shares Offered | 62,53,200 | 100.00% | 100.00% |
Investors can bid for a minimum of 800 shares and in multiples of 400 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 800 | ₹2,74,400 |
| Individual investors (IND) (Max) | 2 | 800 | ₹2,74,400 |
| S-HNI (Min) | 3 | 1,200 | ₹4,11,600 |
| S-HNI (Max) | 7 | 2,800 | ₹9,60,400 |
| B-HNI (Min) | 8 | 3,200 | ₹10,97,600 |
Q-Line Biotec IPO raises ₹61.10 crore from anchor investors. Q-Line Biotec IPO Anchor bid date is May 20, 2026.
| Bid Date | Wed, May 20, 2026 |
| Shares Offered | 17,81,200 |
| Anchor Portion (₹ Cr.) | 61.10 |
| Anchor lock-in period end date for 50% shares (30 Days) | Thu, Jun 25, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Mon, Aug 24, 2026 |
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.
As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.
As on March 31, 2026, the company had 362 permanent employees.
Competitive Strengths:
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| NET Worth | 229.16 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 212.89 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
| Amount in ₹ Crore | ||||
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Earkart Ltd. | SME | ₹49.26 Cr | ₹135 | 20.48 | ₹142.25 | +5.37% | ₹156.55 (+4.82%) |
| Galaxy Medicare Ltd. | SME | ₹22.31 Cr | ₹54 | 19.01 | ₹51.30 | -5.00% | ₹18.30 (-3.68%) |
| Fabtech Technologies Ltd. | Mainboard | ₹230.30 Cr | ₹191 | 13.32 | ₹182.40 | -4.50% | ₹161.65 (+2.73%) |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To meet working capital requirements | 93.50 |
| 2 | Repayment of certain borrowing availed by the Company, in part or full | 90.00 |
| 3 | General Corporate Purposes | 5.10 |
| 4 | Issue Expenses | 25.89 |
| Total | 214.48 |
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 16.88% | 23.74% |
| ROCE | 13.32% | 17.66% |
| Debt/Equity | 1.06 | 0.87 |
| RoNW | 16.88% | 23.74% |
| PAT Margin | 16.65% | 8.97% |
| EBITDA Margin | 27.64% | 22.73% |
| Price to Book Value | 2.44 | 2.84 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 16.47 | 22.12 |
| P/E (x) | 20.82 | 15.51 |
| Promoter Holding | 96.77% | |
| Market Cap | ₹800.16 Cr. |
The Q-Line Biotec IPO IPO subscription status. Full data available on IPOMatrix.com.
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Applications |
|---|---|---|---|---|
| Total | 71.75 | 59,40,000 | 42,62,10,800 | 2,32,607 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manger Fees including Underwriting fees | 11.39 |
| 2 | Fees Payable to Registrar to the Issue | 0.07 |
| 3 | Fees Payable for Advertising and Publishing Expenses | 0.38 |
| 4 | Fees Payable to Regulators including Stock Exchange | 0.16 |
| 5 | Payment for Printing & Stationery, Postage, etc. | 0.03 |
| 6 | Fees Payable to Auditor, Legal Advisors, Monitoring agency fees, fees payable for Industry report and other Professionals | 0.67 |
| 7 | Others (Fees payable for Marketing & distribution expenses, Selling Commission, Brokerage, Processing Fees* and Miscellaneous Expenses) | 13.18 |
| Total | 25.89 |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹343.00 |
| Open | ₹452.00 |
| Low | ₹431.00 |
| High | ₹474.60 |
| Last Trade | ₹474.60 |
Lead Manager Reports
Q-Line Biotec IPO is a SME IPO of 62,53,200 equity shares of the face value of ₹10 aggregating up to ₹214 Crores. The issue is priced at ₹343 per share. The minimum order quantity is 400.
The IPO opens on Thu, May 21, 2026, and closes on Mon, May 25, 2026.
Purva Sharegistry (India) Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Q-Line Biotec IPO using UPI as a payment gateway. Zerodha customers can apply in Q-Line Biotec IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Q-Line Biotec IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Q-Line Biotec IPO opens on Thu, May 21, 2026 and closes on Mon, May 25, 2026.
Q-Line Biotec IPO lot size is 400, and the minimum amount required for application is ₹2,74,400, with 2 lots being the minimum application size.
You can apply in Q-Line Biotec IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Q-Line Biotec IPO will be done on Tuesday, May 26, 2026, and the allotted shares will be credited to your demat account by Wed, May 27, 2026. Check the Q-Line Biotec IPO allotment status.
The Q-Line Biotec IPO listing date is on Fri, May 29, 2026.
